Literature DB >> 15762195

Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus.

Francesco Vendrame1, Carmela Santangelo, Roberta Misasi, Sabrina Dionisi, Chiara Gizzi, Massimo Realacci, Daniele Grassetti, Umberto Di Mario, Francesco Dotta.   

Abstract

OBJECTIVE: Activation-induced cell death (AICD) is a major mechanism in the regulation of peripheral tolerance and its impairment can determine the development of autoimmunity. In the present study, in order to evaluate the role of caspase-3 in type 1 diabetes mellitus (T1DM) AICD, caspase-3 expression was analyzed in peripheral blood lymphocytes from 37 new onset T1DM patients and from 36 normal control subjects (NC) in resting conditions and after anti-Fas-triggered apoptosis.
METHODS: Caspase-3 expression was determined by semiquantitative RT-PCR and Western blot. Apoptosis was induced in activated lymphocytes by anti-Fas monoclonal antibody and quantified by flow cytometry and morphological analysis.
RESULTS: Caspase-3 mRNA expression was reduced in resting lymphocytes in 18/37 T1DM patients and in 1/36 NC (P < 0.01). Patients studied for both Fas-mediated AICD and caspase-3 mRNA expression revealed that a reduced caspase-3 mRNA expression in resting lymphocytes occurred in all patients showing resistance to Fas-mediated apoptosis (T1DM vs NC, P < 0.02) with the exception of 3 patients who exhibited normal caspase-3 expression levels. Caspase-3 protein analysis confirmed mRNA data and showed an impaired expression of caspase-3 active form in T1DM subjects compared with NC.
CONCLUSIONS: Our data show that defective expression and function of caspase-3 in peripheral lymphocytes of T1DM patients may contribute to the development of AICD resistance in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15762195     DOI: 10.1530/eje.1.01813

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  4 in total

1.  A locus on chromosome 1 promotes susceptibility of experimental autoimmune myocarditis and lymphocyte cell death.

Authors:  Davinna L Ligons; Mehmet L Guler; Haiyan S Li; Noel R Rose
Journal:  Clin Immunol       Date:  2008-10-31       Impact factor: 3.969

2.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Authors:  Joanne L Jones; Chia-Ling Phuah; Amanda L Cox; Sara A Thompson; Maria Ban; Jacqueline Shawcross; Amie Walton; Stephen J Sawcer; Alastair Compston; Alasdair J Coles
Journal:  J Clin Invest       Date:  2009-06-22       Impact factor: 14.808

3.  Comment on: Meagher et al. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes 2010;59:2862-2871.

Authors:  Francesco Vendrame; Francesco Dotta
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

4.  Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease Have Altered Concentrations of Key Apoptosis Players: Preliminary Results.

Authors:  Katarzyna Neubauer; Barbara Woźniak-Stolarska; Małgorzata Krzystek-Korpacka
Journal:  Biomed Res Int       Date:  2018-11-01       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.